Press Enter to search · Esc to close
A 2025 network meta-analysis ranks withdrawal and bridging strategies for medication-overuse headache. The combinations win — but the evidence is moderate, not magical.
A secondary analysis of a placebo-controlled trial in patients with alcohol use disorder and obesity found exenatide lowered a blood marker of drinking — but only after months, not weeks.
Two 2025 studies converge on measurable biological signatures that set centenarians—and long-lived mammals—apart. The evidence is intriguing, the mechanisms partial, the hype unwarranted.